Literature DB >> 17664326

Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.

Awadh Bihari Yadav1, Amit Misra.   

Abstract

The relevance of apoptosis to killing of intracellular Mycobacterium tuberculosis was studied with phorbol-differentiated THP-1 cells. Microparticles containing isoniazid and rifabutin induced intrinsic apoptosis and bacterial killing equivalent to that with dissolved drugs and maximally enhanced purinergic P2 receptor activity, while drug-free microparticles induced apoptosis via a different mechanism without killing bacteria.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17664326      PMCID： PMC2043254          DOI： 10.1128/AAC.00925-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Proapoptotic activity of Caenorhabditis elegans CED-4 protein in Drosophila: implicated mechanisms for caspase activation.

Authors:  H Kanuka; S Hisahara; K Sawamoto; S Shoji; H Okano; M Miura
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

2.  In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres.

Authors:  Sandra Prior; Bruno Gander; Natalia Blarer; Hans Peter Merkle; Marija Luisa Subirá; Juan Manuel Irache; Carlos Gamazo
Journal:  Eur J Pharm Sci       Date:  2002-03       Impact factor: 4.384

3.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.

Authors:  S Suarez; P O'Hara; M Kazantseva; C E Newcomer; R Hopfer; D N McMurray; A J Hickey
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

4.  High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.

Authors:  M H Cynamon; Y Zhang; T Harpster; S Cheng; M S DeStefano
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Failure of a prothionamide-containing oral antituberculosis regimen.

Authors:  M E Langton; R L Cowie
Journal:  S Afr Med J       Date:  1985-12-07

6.  Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.

Authors:  R Sharma; D Saxena; A K Dwivedi; A Misra
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

7.  Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages.

Authors:  C Fratazzi; R D Arbeit; C Carini; H G Remold
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

8.  THP-1 cell apoptosis in response to Mycobacterial infection.

Authors:  Carrie J Riendeau; Hardy Kornfeld
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  Inhalable microparticles containing large payload of anti-tuberculosis drugs.

Authors:  Pavan Muttil; Jatinder Kaur; Kaushlendra Kumar; Awadh Bihari Yadav; Rolee Sharma; Amit Misra
Journal:  Eur J Pharm Sci       Date:  2007-07-04       Impact factor: 4.384

10.  Role of phagocytosis in the activation of macrophages.

Authors:  J Schnyder; M Baggiolini
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307
View more
  4 in total

1.  Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.

Authors:  Rahul Kumar Verma; Jatinder Kaur; Kaushlendra Kumar; Awadh Bihari Yadav; Amit Misra
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 2.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

3.  Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb).

Authors:  C Lawlor; M P O'Sullivan; B Rice; P Dillon; P J Gallagher; S O'Leary; S Shoyele; J Keane; S-A Cryan
Journal:  J Mater Sci Mater Med       Date:  2011-12-20       Impact factor: 3.896

4.  An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages.

Authors:  Tatiany J de Faria; Mariane Roman; Nicole M de Souza; Rodrigo De Vecchi; João Vitor de Assis; Ana Lúcia Gomes dos Santos; Ivan H Bechtold; Nathalie Winter; Maurilio José Soares; Luciano Paulino Silva; Mauro V De Almeida; André Báfica
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.